R. Hui

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer

A. Tafreshi, M. O'Brien, J. Brahmer, 2019, Journal of Thoracic Oncology.

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

V. Gebski, R. Balleine, R. Kefford, 2016, Clinical Cancer Research.

Three-year overall survival update from the PACIFIC trial.

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?

R. Balleine, N. Wilcken, C. Liddle, 2019, Breast.

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2021 .

Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

C. Faivre-Finn, J. Vansteenkiste, J. Naidoo, 2022, Lung cancer.

FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

E. Esteban, S. Gadgeel, J. Gray, 2021 .

Overexpression of Cyclin D 1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer 1

R. Blamey, J. Robertson, R. Nicholson, 1999 .

459PRisk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001

M. Ahn, S. Ramalingam, M. Hellmann, 2015 .

Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189.

E. Felip, E. Esteban, M. Pietanza, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

D. Planchard, C. Faivre-Finn, S. Senan, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).

M. Dolled-Filhart, K. Emancipator, N. Rizvi, 2014 .

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.

Y. Shentu, A. Tafreshi, M. O'Brien, 2017 .

Trastuzumab‐Induced Cardiotoxicity: The Role of Two‐Dimensional Myocardial Strain Imaging in Diagnosis and Management

S. Meikle, D. Richards, L. Thomas, 2012, Echocardiography.

Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing

S. Fox, J. Graham, M. Brennan, 2021, Breast Cancer Research and Treatment.

Cyclins and breast cancer

R. Sutherland, C. K. Watts, E. Musgrove, 2005, Journal of Mammary Gland Biology and Neoplasia.

CDK4/6 inhibitor plus endocrine therapy for hormone receptor‐positive, HER2‐negative metastatic breast cancer: The new standard of care

E. Lim, J. Lynch, R. Hui, 2021, Asia-Pacific journal of clinical oncology.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2018, The New England journal of medicine.

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.

D. Planchard, C. Faivre-Finn, S. Senan, 2021, Future oncology.

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

P. Fasching, L. Pusztai, C. Denkert, 2021 .

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

E. Felip, E. Esteban, M. Pietanza, 2020, The Lancet. Oncology.

Cyclin-dependent kinases as downstream targets of oestrogen action: potential prognostic indicators and therapeutic targets

R. Sutherland, O. Prall, C. K. Watts, 1997 .

J. Carroll, R. Sutherland, E. Musgrove, 2003 .

EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival

J. Forbes, R. Blamey, J. Robertson, 1998, Oncogene.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

J. Lunceford, M. Ayers, B. Halmos, 2022, JTO clinical and research reports.

Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.

N. Pavlakis, A. Nagrial, A. Gill, 2021, Lung cancer.

Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres

A. Nagrial, M. Carlino, R. Hui, 2022, Cancer medicine.

E. Felip, M. Pietanza, S. Gadgeel, 2018 .

Epidermal growth factor receptor inhibitor‐induced papulopustular eruption successfully treated with low‐dose oral dapsone

R. Hui, P. Fernández-Peñas, C. Zhao, 2018, The Australasian journal of dermatology.

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.

R. Blamey, J. Robertson, R. Nicholson, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer.

R. Blamey, R. Nicholson, J. Robertson, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2018, Journal of Thoracic Oncology.

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

J. Lunceford, M. Ayers, E. Felip, 2019, Journal of Thoracic Oncology.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

A. Giobbie-Hurder, S. Loi, G. Viale, 2019, The Lancet. Oncology.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

M. Ahn, E. Felip, S. Ramalingam, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.

J. Carroll, R. Sutherland, E. Musgrove, 2002, Cancer research.

Pembrolizumab for Early Triple-Negative Breast Cancer.

P. Fasching, J. Bergh, L. Pusztai, 2020, The New England journal of medicine.

Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.

J. Carroll, R. Sutherland, E. Musgrove, 2003, Endocrine-related cancer.

International Congress on Hormonal Steroids and Hormones and Cancer Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells

J. Carroll, R. Sutherland, E. Musgrove, 2003 .

INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.

R. Blamey, J. Robertson, R. Nicholson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

INK 4 a Gene Expression and Methylation in Primary Breast Cancer : Overexpression of p 16 INK 4 a Messenger RNA Is a Marker of Poor Prognosis 1

R. Blamey, J. Robertson, R. Nicholson, 2000 .

Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors

M. Millward, R. Hui, 2019, Pulmonary Adenocarcinoma: Approaches to Treatment.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

M. Ahn, E. Felip, K. Emancipator, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer

Robert L. Sutherland, Roger J. Daly, R. Sutherland, 2003, Breast Cancer Research and Treatment.

973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

P. Schwarzenberger, J. Gray, M. Reck, 2022, Annals of Oncology.

Up‐regulation of the protein tyrosine phosphatase SHP‐1 in human breast cancer and correlation with GRB2 expression

R. Blamey, J. Robertson, R. Nicholson, 2000, International journal of cancer.

KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.

E. Felip, E. Esteban, M. Pietanza, 2019, Journal of Clinical Oncology.

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

H. Rugo, M. Gnant, H. Iwata, 2020, Clinical breast cancer.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

J. Lunceford, M. Ayers, Ying Cheng, 2019, Annals of Oncology.

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

M. Dolled-Filhart, K. Emancipator, N. Rizvi, 2014 .

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer

D. Horsfall, R. Sutherland, E. Musgrove, 1997, Oncogene.

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

A. Mansfield, R. Herbst, T. Mok, 2021, JTO clinical and research reports.

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

C. Faivre-Finn, S. Senan, L. Paz-Ares, 2020, Lung cancer.

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Charu Aggarwal, Myung-Ju Ahn, Edward B Garon, 2019, The Lancet. Respiratory medicine.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

A. Tafreshi, M. Pietanza, M. O'Brien, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing care for younger women with hormone receptor‐positive, HER2‐negative metastatic breast cancer

E. Lim, R. Hui, B. Yeo, 2020, Asia-Pacific journal of clinical oncology.

Physical activity for symptom management in women with metastatic breast cancer: a randomised feasibility trial.

G. Davis, D. Currow, J. Yee, 2019, Journal of pain and symptom management.

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Niladri Roy Chowdhury, T. Hu, R. Ramesh, 2022, Journal for ImmunoTherapy of Cancer.

Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials

V. Gebski, R. Hui, A. Mulvey, 2021, JNCI cancer spectrum.

Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.

J. Gregg, A. Marchetti, J. Subramanian, 2022, Lung cancer.

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

P. Fasching, L. Pusztai, C. Denkert, 2022, The New England journal of medicine.

PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases.

R. Hui, P. Fernández-Peñas, S. Hwang, 2016, Melanoma research.

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

S. Loi, D. Cescon, V. Karantza, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Gregory Riely, R. Hui, K. Park, 2018, Journal of Thoracic Oncology.

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

E. Winer, S. Loi, D. Cescon, 2017 .

PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024

A. Tafreshi, M. O'Brien, J. Brahmer, 2017 .

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

P. Dennis, B. Cho, Yiduo Zhang, 2019, The Lancet. Oncology.

LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

A. Tafreshi, J. Riess, M. Pietanza, 2020 .

Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).

M. Dolled-Filhart, K. Emancipator, J. Soria, 2014 .

135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

C. Denkert, H. McArthur, S. Kuemmel, 2022, Annals of Oncology.

A. Tafreshi, M. O'Brien, J. Brahmer, 2017, The Lancet. Oncology.

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm

E. Lim, J. Beith, A. Redfern, 2018, Asia-Pacific journal of clinical oncology.

Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial

H. P. van der Ploeg, S. Clarke, H. Dhillon, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study

T. Marwick, D. Richards, A. Boyd, 2017, PloS one.

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan, Y. Wu, H. Mann, 2022, ESMO open.

Physical activity and fitness in women with metastatic breast cancer

G. Davis, D. Currow, J. Yee, 2013, Journal of Cancer Survivorship.

Physical activity and fitness in women with metastatic breast cancer.

G. Davis, D. Currow, J. Beith, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy.

S. Meikle, D. Richards, L. Thomas, 2011, Heart, lung & circulation.

Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.

S. Meikle, D. Richards, A. Boyd, 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

P. Fasching, L. Pusztai, C. Denkert, 2019, Annals of Oncology.

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

A. Nagrial, R. Hui, E. Hau, 2023, Thoracic cancer.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

E. Felip, M. Hellmann, M. Chatterjee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.

M. Ahn, E. Felip, K. Emancipator, 2015 .

Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

Michael P. Morrissey, M. Ayers, E. Felip, 2020 .

LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC

D. Planchard, L. Paz-Ares, P. Dennis, 2017 .

Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.

M. Ahn, E. Felip, S. Ramalingam, 2019, Journal of Clinical Oncology.

Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042

A. Mansfield, R. Herbst, T. Mok, 2019, Annals of Oncology.

OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%

A. Tafreshi, M. Pietanza, M. O'Brien, 2017 .

Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation

V. Gebski, R. Balleine, R. Kefford, 2013 .

Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

Niladri Roy Chowdhury, E. Kwak, D. Tan, 2018 .

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

J. Lunceford, M. Dolled-Filhart, K. Emancipator, 2014 .

Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2019, Annals of Oncology.

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Ying Cheng, B. Halmos, L. Paz-Ares, 2018, Journal of Thoracic Oncology.

KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

J. Lunceford, M. Ayers, E. Felip, 2019 .

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

M. A. Ayers, R. Herbst, Yi-long Wu, 2021, Journal for ImmunoTherapy of Cancer.

A. Nagrial, S. Kao, B. McCaughan, 2022, Asia-Pacific journal of clinical oncology.

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Y. Shentu, A. Tafreshi, M. O'Brien, 2016 .

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio

R. Mathijssen, P. de Bruijn, N. Wilcken, 2020, Breast.

Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis.

E. Tan, A. Szczesna, O. Bertetto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.

M. Krzakowski, U. Gatzemeier, E. Tan, 2005, Lung cancer.

PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC

P. Dennis, B. Cho, S. Antonia, 2017 .

KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.

M. Ahn, E. Felip, S. Ramalingam, 2017 .

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

M. Ahn, E. Felip, S. Ramalingam, 2016 .

Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)

M. Ahn, E. Felip, K. Emancipator, 2015 .

Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.

S. Meikle, D. Richards, A. Boyd, 2013, European heart journal cardiovascular Imaging.

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.

D. Juric, M. Campone, P. Munster, 2016 .

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

P. Fasching, L. Pusztai, C. Denkert, 2022, Cancer Research.

4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.

M. Ahn, E. Felip, S. Ramalingam, 2018 .

P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer: Topic: IT

A. Nagrial, R. Hui, M. Crumbaker, 2017 .

Three-year overall survival update from the PACIFIC trial

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Annals of Oncology.

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

E. Felip, E. Esteban, M. Pietanza, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC

E. Felip, E. Esteban, M. Pietanza, 2019, Journal of Thoracic Oncology.

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

E. Felip, E. Esteban, M. Pietanza, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.

R. Herbst, J. Soria, M. Hellmann, 2017 .

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.

P. Fasching, J. Bergh, L. Pusztai, 2022, Journal of Clinical Oncology.

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

S. Novello, E. Felip, E. Esteban, 2018, Clinical Trials.

1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)

P. Fasching, L. Pusztai, C. Denkert, 2020 .

Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.

R. Herbst, M. Nishio, M. Reck, 2019, Journal of Clinical Oncology.

ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non–small cell lung cancer (mNSCLC).

M. Garassino, R. Hui, Yi Luo, 2018 .

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.

C. Faivre-Finn, S. Senan, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

S. Novello, E. Felip, E. Esteban, 2018, The New England journal of medicine.

Management of Early Breast Cancer at an Australian Cancer Centre During the Early Phase of COVID-19 Pandemic

W. Wang, M. Brennan, J. French, 2021, Archives of Breast Cancer.

Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.

S. Meikle, D. Richards, L. Thomas, 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

Up‐regulation of the protein tyrosine phosphatase SHP‐1 in human breast cancer and correlation with GRB2 expression

R. Blamey, J. Robertson, R. Nicholson, 2000, International journal of cancer.

Patterns of care for stage III non–small cell lung cancer in Australia

S. Kao, B. Chan, B. Hughes, 2019, Asia-Pacific journal of clinical oncology.